A carregar...
Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan
Antibody-drug conjugates (ADCs) that exploit the active metabolite SN-38, which is derived from the popular anticancer drug, irinotecan (a camptothecin that inhibits the nuclear topoisomerase I enzyme, inducing double-stranded DNA breaks during the mitotic S-phase of affected cells), represent a sub...
Na minha lista:
| Publicado no: | MAbs |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6748572/ https://ncbi.nlm.nih.gov/pubmed/31208270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2019.1632115 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|